Strategic Partnership Between Camurus and Eli Lilly for the Development of Long-Acting Incretin Therapies
Reading Time: 2 minutes
On June 3, 2025, the Swedish biopharmaceutical company Camurus and the US pharmaceutical company Eli Lilly announced a comprehensive collaboration and licensing agreement. The goal of this partnership is the development and global marketing of long-acting incretin-based therapies for the treatment of obesity, diabetes, and other cardiometabolic diseases. Lilly's expertise in metabolic disorders is combined with Camurus' patented FluidCrystal technology. The agreement includes up to four proprietary compounds from Lilly, including dual GIP and GLP-1...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
